TQB2928 not checked

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects. Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug.”In the company’s words, NCT06585059 on ClinicalTrials.gov
Tested for
Advanced Non-small Cell Lung Cancer
Main trialPhase 1
“This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II dose (RP2CD).”In the company’s words, NCT06585059 on ClinicalTrials.gov

Other drugs for Advanced Non-small Cell Lung Cancer

All 560 drugs for Advanced Non-small Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Dec 2025 Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
Phase 1Unknown 1 Jul 2022 Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
Phase 1Unknown Jan 2024 Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
Phase 1Terminated 31 Jul 2024 TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
Phase 1Unknown May 2025 Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Phase 1Terminated 18 Jun 2025 TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQB2928

Following is part of Solo: you see every change to TQB2928 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in